Updated October 14, 2026 · By Rob Braddock
Reliable radiopharmaceutical manufacturing requires more than a working synthesis process. Manufacturers must coordinate material availability, qualified facilities, trained staff, quality decisions, radiation protection, and delivery within a product’s usable life. This guide gives operations leaders a practical way to assess readiness and identify gaps before they disrupt a batch.
Start here: Confirm the applicable GMP framework, map the complete batch timeline, assign responsibility for release decisions, and test the most likely operational failure scenarios.
What Makes Radiopharmaceutical Manufacturing Different?
Radioactive decay makes elapsed time an operational constraint. A delay in material receipt, production, testing, or dispatch can change the activity available at a specified time. Product stability, storage conditions, transport arrangements, and patient scheduling can add further constraints. Build the manufacturing plan around the actual product and process rather than assuming every radiopharmaceutical follows the same workflow.
Confirm the GMP and Licensing Framework
FDA identifies 21 CFR Parts 210 and 211 as the general drug CGMP framework and Part 212 as the framework for PET drugs. Do not assume Part 212 applies to every diagnostic or therapeutic radiopharmaceutical. The product type, development stage, and applicable requirements need to be established before procedures and qualification plans are finalized. See FDA’s CGMP regulations overview and its PET drug CGMP guidance.
Drug quality oversight and radioactive materials licensing address different responsibilities. Determine whether the NRC or an Agreement State is the relevant materials regulator for the proposed activity and location. Consult the responsible radiation safety and regulatory specialists. The NRC Agreement States page provides a starting point.
A Practical Radiopharmaceutical Readiness Checklist
| Readiness area | What to check | Evidence to review | Suggested leads |
|---|---|---|---|
| Product and requirements | Confirm intended product, development stage, applicable GMP framework, and licensed activities. | Documented requirements review and responsibility map. | Quality, regulatory, radiation safety |
| Isotope and critical materials | Check delivery windows, receipt criteria, supplier status, and response to a missed shipment. | Supplier records, receiving procedure, contingency contacts. | Supply chain and operations |
| Facilities, utilities, and equipment | Review qualification status, open changes, calibration, maintenance, and critical utilities for the intended process. | Approved records, equipment status list, unresolved gap log. | Engineering and quality |
| Aseptic processing, where applicable | Review contamination controls, cleaning, interventions, environmental monitoring, and process simulation status. | Applicable validation records, monitoring trends, approved procedures. | Manufacturing and quality |
| People and coverage | Confirm task qualifications, staffing across the production window, and backup for critical roles. | Training matrix, shift coverage plan, escalation contacts. | Operations and department leads |
| Batch records and testing | Confirm current instructions, available testing resources, sample handoffs, and review responsibilities. | Approved batch records, specifications, testing schedule. | Manufacturing and quality control |
| Quality review and release | Define authorized decisions, required results, deviation handling, and handoffs before dispatch. | Release procedure, decision responsibilities, escalation rules. | Quality unit |
| Packaging and distribution | Check activity reference times, usable life, storage conditions, transport arrangements, and dispatch checks. | Packaging records, handling instructions, delivery plan. | Logistics, operations, radiation safety |
| Interruptions and recovery | Walk through a late delivery, equipment fault, unavailable analyst, and utility interruption. | Scenario review, recovery procedures, assigned actions. | Cross functional team |
How to Turn the Checklist into a Startup Decision
Use this checklist as an operations planning tool. Adapt the evidence and responsibilities to the product, process, and approved site procedures. It does not replace product specific requirements, validation, licensing, or quality release decisions.
- Define the planned activity. State whether the review supports a new facility, product transfer, capacity increase, or restart. Identify the intended production date and scope.
- Review evidence with the responsible teams. Mark each item ready, action required, or not applicable. Record the document reference and explain any not applicable decision.
- Assign every gap. Record the operational or quality impact, owner, due date, and evidence needed for closure. Separate issues that must be resolved before startup from improvements that can follow under approved controls.
- Walk through the batch timeline. Test handoffs and interruption scenarios with operations, engineering, quality, supply chain, and radiation safety. Confirm who makes each decision.
- Document the readiness review. Summarize open items, approved controls, and responsible approvals through site procedures. Revisit the assessment after significant changes.
Illustrative gap: A qualified production system is available, but the only trained analyst is absent during the planned batch window. The readiness action is to confirm qualified testing coverage and the approved testing and review sequence before committing to that schedule. Equipment availability alone does not establish readiness.
Radiopharmaceutical Equipment: Selection, Qualification, and Maintenance
Radiopharmaceutical equipment should fit the isotope, product, process, batch size, and operating schedule. A facility receiving an isotope has different needs from one producing it onsite. Define the intended use and acceptance criteria before selecting a vendor, then involve manufacturing, engineering, quality, and radiation safety in the review.
| Equipment category | Selection questions | Readiness evidence |
|---|---|---|
| Isotope production or receipt systems | Is onsite production needed? Can receipt and transfer support the planned activity and timing? | Documented supply strategy, transfer interfaces, and receipt procedures. |
| Hot cells, shielding, and remote handling | Does the design address the isotope, activity, operator tasks, access, and contamination risks? | Radiation safety assessment, design review, and applicable containment verification. |
| Synthesis, purification, and formulation systems | Are materials compatible? Can the system support cleaning, changeover, and required process controls? | Approved requirements, qualification records, and process verification. |
| Dispensing and aseptic processing equipment | Can staff perform routine tasks and interventions while maintaining required contamination controls? | Applicable qualification, cleaning evidence, and aseptic process simulation records. |
| Activity measurement and analytical instruments | Are measurement range, method suitability, instrument availability, and testing time adequate? | Calibration status, applicable method validation or verification, and trained analyst coverage. |
| Packaging and dispatch equipment | Can the packaging system meet product conditions and applicable radioactive material transport requirements? | Packaging evidence, approved shipping procedures, and dispatch checks. |
Build the qualification plan around intended use and risk. Review installation, operating ranges, alarms, interfaces, and performance under representative conditions. FDA’s equipment guidance addresses design, cleaning, maintenance, and product contact surfaces under Part 211. Its PET CGMP compliance guide explains equipment expectations under Part 212. Apply the framework appropriate to the product.
Plan maintenance access before startup. Identify spare parts, service response times, safe access after radioactive work, and backup for shared instruments. After repair, assess the impact on qualified status and document required verification before return to service. Shielding and contamination controls need coordinated review; one does not establish the adequacy of the other. See NRC guidance on radiation protection.
How Do Isotope Half-Lives Affect Radiopharmaceutical Delivery?
Radioactive decay reduces activity during production, testing, review, and transport. Plan backward from the required activity at the agreed reference time. Include realistic handoff times and delay scenarios alongside product expiry, stability, and approved release requirements.
Illustrative calculation: For an isotope with a hypothetical two-hour physical half-life, 100 activity units become 50 after two hours and 25 after four hours, considering physical decay alone. The relationship is A(t) = A(0) × 2−t/T, where T is the half-life and t uses the same time units. This planning example does not establish a usable shelf life, release limit, or patient dose.
- Align isotope availability, batch start, testing, authorized review, and courier collection.
- Confirm the receiving site’s acceptance window and activity reference time.
- Set escalation points for missed collection, equipment failure, and delayed test results.
- Assign dispatch decisions and contingency actions through approved procedures.
Transport planning must also address applicable packaging, marking, labeling, documentation, and training requirements. NRC and DOT share oversight of radioactive material transport; consult the NRC transportation overview and involve qualified shipping and radiation safety personnel. For help connecting equipment, staffing, and delivery constraints, explore PharmExcel’s radiopharmaceutical consulting services.
Map the Batch Timeline Before Adding Capacity
Create one timeline from material receipt through dispatch. Include preparation, synthesis or formulation, purification where applicable, dispensing, required testing, review, and handoffs. Record both processing time and waiting time. A synthesis step may look efficient while review queues or a shared instrument limit the entire operation.
- Identify shared equipment, specialist staffing, and quality review constraints.
- Define the expected response to a late delivery, equipment fault, or unavailable analyst.
- Make escalation rules clear before the production window begins.
- Review the complete workflow when increasing batch frequency or adding a new product.
Keep Aseptic Controls Separate from Radiation Protection
Radiation shielding and remote handling do not replace contamination controls. Where aseptic processing is used, evaluate the effect of equipment access, interventions, personnel practices, and cleaning on the process. For sterile PET drugs made under Part 212, FDA provides specific media fill guidance. Apply the guidance within its stated scope.
Common Operational Gaps to Check
- A production plan that excludes quality review and dispatch time.
- Unclear ownership of deviations or decisions during an interruption.
- Maintenance plans that do not consider access restrictions or production schedules.
- Training that covers routine work but leaves exception handling unclear.
- Expansion plans based on equipment capacity alone.
Frequently Asked Questions
Does every radiopharmaceutical use the same GMP requirements?
No. PET drugs have a distinct CGMP framework. Confirm the requirements for the specific product and activity.
What should a readiness assessment produce?
A prioritized gap list with risk, owner, required evidence, and completion dates. It should identify what must be resolved before the planned activity proceeds.
Should qualification be reviewed after a change?
Assess the change against the qualified process, equipment, and intended use. Document the rationale and any verification needed through the site’s approved procedures.
Get Support with Manufacturing Readiness
Planning a radiopharmaceutical facility startup, product transfer, or capacity increase? Rob Braddock brings former COO experience at Evergreen Theragnostics to practical operations planning. PharmExcel can help map the batch workflow, assess facility and manufacturing systems, clarify team responsibilities, and build a prioritized action plan. Explore our facility readiness and manufacturing operations consulting services, or request a consultation about your radiopharmaceutical manufacturing readiness. Bring your target date, current process map, and main concerns to the discussion.
About the Author
Rob Braddock is the founder of PharmExcel Consulting, former COO of Evergreen Theragnostics, and former Executive Director of Manufacturing Operations at BioCentriq. His career includes manufacturing leadership roles at Pfizer/Wyeth Vaccines and Chemtrade. Learn more about PharmExcel.